Mural Oncology's (MURA) shares jumped more than 160% in recent trading Tuesday after the company said it is discontinuing all clinical development of nemvaleukin alfa and plans to immediately start exploring strategic alternatives.
The move follows the review of data from its phase 2 ARTISTRY-6 trial in melanoma, which failed to achieve the primary endpoint, and previously announced adverse results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the Ireland-based clinical-stage immuno-oncology company said.
The company has engaged Lucid Capital Markets LLC as financial adviser for the exploration of strategic alternatives, which would include an offer for or other acquisition of the company, merger, or business combination. The company also said it will reduce its workforce by roughly 90%.
As of Dec. 31, 2024, the company had approximately $144.4 million of cash and cash equivalents, and marketable securities.
Price: 3.02, Change: +1.99, Percent Change: +193.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。